Allele, SCM Lifescience sign joint research and development agreement to develop iPSC-based diabetes treatment

This article was originally published here

iPSCs can be derived from adult human tissue cells yet share the developmental potentials of embryonic stem cells. Currently Japan has 6 ongoing clinical trials utilizing this technology,

The post Allele, SCM Lifescience sign joint research and development agreement to develop iPSC-based diabetes treatment appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply